Taking probiotics where they’ve never gone before
PharmaVoice
AUGUST 2, 2022
How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.
Tue.Aug 02, 2022
264 
Regional Trends Reinforcing Breast Cancer Therapeutics Market
Pharmacy Times
AUGUST 2, 2022
Over the next few years, undiagnosed breast cancer cases may add to the demand for more rigorous end-stage treatments and therapeutics.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Celebrating Medicare’s 57th anniversary
PhRMA
AUGUST 2, 2022
In case you missed it, Saturday, July 30, marked the anniversary of Medicare. For 57 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans with certain medical needs. To celebrate, we are reflecting on the history of the program that benefits more than 60 million Americans. Unfortunately, some members of Congress are considering significant changes to Medicare that could have a devastating effect on millions of Americans.
Facilities in Non-Hispanic Black, Rural Counties Less Likely to Administer Early COVID-19 Vaccines
Pharmacy Times
AUGUST 2, 2022
Health care facilities in counties with higher Black populations and in rural areas were less likely to serve as COVID-19 vaccination facilities during May 2021, indicating disparities in vaccine distribution.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Roche scores phase 3 win for subcutaneous Tecentriq, eyes filings
pharmaphorum
AUGUST 2, 2022
Roche’s Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous formulation, after the new version matched the original intravenous formulation in a phase 3 trial. The results of the IMscin001 study found that an injection of Tecentriq under the skin taking just a few minutes was non-inferior to a 30 to 60-minute infusion with the IV version in terms of pharmacokinetics – how the active ingredient behaves in the body after administration.
Computationally Developed Cocktail for HIV Therapy Significantly Reduces Chance of Viral Rebound
Pharmacy Times
AUGUST 2, 2022
Using computational methods, the development of an HIV therapy cocktail based on the virus’ genetics was found to increase the efficacy of treatment.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Deep Brain Stimulation System May Help Manage Severe Depression
Pharmacy Times
AUGUST 2, 2022
Abbott will work with the FDA to expedite the review of their deep brain stimulation system to treat the life-threatening disease of treatment-resistant depression.
Blending human knowhow, artificial intelligence aids drug discovery
Outsourcing Pharma
AUGUST 2, 2022
A leader from pharmaceutical firm Astellas discusses how the company has put to use a discovery platform that combines human expertise, AI, and robotics.
Eating High Amounts of Ultra-Processed Foods Associated with Increased Risk of Dementia
Pharmacy Times
AUGUST 2, 2022
For every 10% increase in daily intake of ultra-processed foods, people had a 25% higher risk of dementia, though the association is not proven to be causal.
Oncology market dominance: As easy as ADC?
pharmaphorum
AUGUST 2, 2022
Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing number of approvals. Ben Hargreaves examines why the interest in the area is growing, at the same time as others express doubts about its potential. Antibody-drug conjugates (ADCs) are a class of biologic drugs designed for targeted treatment of cancer.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Study: Transgender Children at Higher Risk for Mental Health Problems
Pharmacy Times
AUGUST 2, 2022
Transgender children were more susceptible to depression, anxiety, and other mental health issues than their cisgender counterparts.
AbbVie taps Sosei Heptares GPCR expertise with $1.2bn+ alliance
pharmaphorum
AUGUST 2, 2022
Sosei Heptares has signed up a string of big pharma collaborators over the last few years, and one of them – AbbVie – has just expanded its partnership with a new to deal to apply the biotech’s G protein-coupled receptor (GPCR) expertise to the discovery of drugs for neurological diseases. The collaboration adds to an earlier drug discovery agreement in the area of immunology and inflammation which dates back to June 2020, suggesting AbbVie likes what it has seen in the earlier alliance.
Study: Depictions of Diverse Women in STEM on Social Media Can Alleviate Loneliness for Other Women in STEM
Pharmacy Times
AUGUST 2, 2022
A new case study found that depictions of diverse female scientists on social media inspired other women in STEM, but stereotypes of how women in STEM should look and dress persist in comments section.
Litifilimab reduces skin disease activity in CLE trial
European Pharmaceutical Review
AUGUST 2, 2022
New Phase II data demonstrates that treatment with Biogen’s litifilimab (BIIB059) was superior in reducing skin disease activity of cutaneous lupus erythematosus (CLE) to placebo over a period of 16 weeks. The results of the Phase II LILAC study Part B were published in The New England Journal of Medicine ( NEJM ). CLE, a type of lupus, is a chronic autoimmune skin disease.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
AbbVie Submits Applications to EMA, FDA for Upadacitinib to Treat Crohn Disease
Pharmacy Times
AUGUST 2, 2022
Submissions are based on 3 phase 3 clinical trials showing that the drug achieved the co-primary endpoints of clinical remission and endoscopic response as induction and maintenance treatment.
Bilingual staff boost Spanish speaker interest in trials: study
Outsourcing Pharma
AUGUST 2, 2022
A survey by SubjectWell indicates that having Spanish-speaking research personnel increases interest in trial participation among Latino potential patients.
Shionogi starts pivotal Japanese trial of Akili’s ADHD app
pharmaphorum
AUGUST 2, 2022
A Japanese language version of Akili Interactive’s EndeavorRx ground-breaking digital therapy for attention deficit hyperactivity disorder (ADHD) has started a phase 3 trial, with results due next year. The study is being conducted by Japanese drugmaker Shionogi, which formed a strategic partnership with Akili in 2019 to bring digital therapeutics (DTx) to Asian markets.
An Overview of the National Lipid Association’s New Recommendations for Managing Statin Intolerance
Pharmacy Times
AUGUST 2, 2022
Pharmacists have a key role in monitoring patients on statin therapy and identifying statin intolerance.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
EC’s HERA signs Covid-19 vaccine procurement deal with HIPRA
Pharmaceutical Technology
AUGUST 2, 2022
The Health Emergency Preparedness and Response Authority (HERA) of the European Commission (EC) has entered a co-procurement framework contract for HIPRA HUMAN HEALTH’s bivalent recombinant protein Covid-19 vaccine. A total of 14 member states and countries are participating in this deal and can procure up to 250 million vaccine doses. . Once the HIPRA vaccine receives a positive assessment from the European Medicines Agency (EMA), this contract will aid in making the doses available rapidly to
Vaccine-related Fears Reduce Vaccine Uptake, Increase Vasovagal Symptoms for Flu, COVID-19 Vaccines
Pharmacy Times
AUGUST 2, 2022
Young age was associated with vaccine-related fears that lowered vaccine uptake and increased symptoms of dizziness and lightheadedness during vaccination.
Implementation of electronic health records will improve the quality of care
Pharmaceutical Technology
AUGUST 2, 2022
The increasing digitisation of the healthcare sector is enabling real-time access to patient-related data in a manner that was not previously possible. With more healthcare facilities transitioning from paper charts to electronic records and electronic health records (EHRs) becoming more integrated and technologically advanced, EHRs are expected to drive big changes in the provision of healthcare and clinical research delivery.
Oncology Overview: Safe Use of Oral Tyrosine Kinase Inhibitors in Thoracic Oncology
Pharmacy Times
AUGUST 2, 2022
Pharmacists have the potential to help optimize treatment and maximize supportive care management for targeted therapies.
Sosei Heptares and AbbVie to develop therapies for neurological ailments
Pharmaceutical Technology
AUGUST 2, 2022
Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. Under the deal, the companies will develop small molecules that can modulate new G protein-coupled receptor (GPCR) targets linked to neurological diseases.
Daily OTC Pearl: NauseaCalm
Pharmacy Times
AUGUST 2, 2022
NauseaCalm relieves nausea and vomiting to treat the symptoms of upset stomach and the stomach flu.
Dexcom ONE glucose monitoring system available on prescription
Pharma Times
AUGUST 2, 2022
System improves management for people with diabetes by offering finger prick-free monitoring
Daily Medication Pearl: Omadacycline (Nuzyra)
Pharmacy Times
AUGUST 2, 2022
Omadacycline (Nuzyra) is indicated for the treatment of adult patients with infections caused by susceptible microorganisms—community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
How Real-Time Data Helps Business Development Teams with New Product Acquisition Research
InCrowd
AUGUST 2, 2022
Learn why a pharmaceutical company considering acquiring a new product asset in a space with noticeable market movement turned to InCrowd’s global qualitative and quantitative solutions to uncover opportunities in product administration and identify an unmet market need. Get the results in our latest case study. The post How Real-Time Data Helps Business Development Teams with New Product Acquisition Research appeared first on InCrowd.
How to Increase Organic Traffic to Your Pharmacy Website with Google Analytics – BLOG #73
The Social Pharmacist
AUGUST 2, 2022
The constantly changing algorithms and the evolving industry significantly impact how Google and other search engines generate organic traffic for a website. SEO-friendly pharmacy businesses or websites benefit from higher visitor traffic, improved brand awareness, and increased customer conversion rates. Companies start generating leads from health services and practices.
AC Immune tries to resurrect crenezumab with new data delve
pharmaphorum
AUGUST 2, 2022
In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab – missed the mark in another clinical trial and looked destined for the scrap heap like so many drugs in the class before it. The failed phase 2 API-ADAD trial in a rare, inherited form of the disease came after Roche abandoned two other phase 3 trials of crenezumab in people with prodromal to mild sporadic Alzheimer’s, and seemed all but certain to spell the end of the programme.
Q&A with Jason Smith, CTO at Within3
PharmExec
AUGUST 2, 2022
Jason Smith discusses his work with AI-based data platforms.
Shaping Strategies for a New Era of Engagement and Commercialization
Pharmaceutical Commerce
AUGUST 2, 2022
With the business model changing and the patent cliff looming, Ashfield Engage's Chris Savage talks about what these upheavals mean for pharma companies, their sales reps, and their patients.
US FDA grants approval for Janssen’s Stelara to treat psoriatic arthritis
Pharmaceutical Technology
AUGUST 2, 2022
The US Food and Drug Administration (FDA) has granted approval for the Janssen Pharmaceutical Companies of Johnson & Johnson (J&J) ’s Stelara (ustekinumab) to treat paediatric patients aged six years and above with active psoriatic arthritis (PsA). The latest approval was based on pharmacokinetic (PK) findings and extrapolation of the validated efficacy and current safety profile of Stelara in various Phase III clinical trials carried out in adult and paediatric moderate-to-severe plaque
SCHOTT Creates Stand-alone Company for Pharma Business
Pharmaceutical Commerce
AUGUST 2, 2022
Division will operate under SCHOTT Pharma AG & Co. KGaA.
Let's personalize your content